Corvus Pharmaceuticals (CRVS) Q1 2026 Earnings
CRVS·Reported May 7, 2026·After market close
Diluted EPS came in at $-0.15 (-15.4% YoY), missed the $-0.14 consensus by $0.01.
Diluted EPS
$-0.15missed by $0.01
Consensus: $-0.14
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Corvus Pharmaceuticals's Q1 2026 earnings report.
Corvus Pharmaceuticals (CRVS) reported Q1 2026 earnings on May 7, 2026 after market close.
Corvus Pharmaceuticals reported diluted EPS of $-0.15 for Q1 2026.
EPS missed the consensus estimate of $-0.14 by $0.01.
Compared to the same quarter a year prior, diluted EPS declined 15.4% from $-0.13.
You can read the 8-K earnings release (0001171843-26-003154) and the 10-Q periodic report (0001104659-26-057100) directly on SEC EDGAR. The filing index links above go to sec.gov.